Abstract
Botulinum neurotoxins (BoNTs) are a growing family of bacterial protein toxins that cause botulism, a rare but often fatal animal and human disease. They are the most potent toxins known owing to their molecular architecture, which underlies their mechanism of action. BoNTs target peripheral nerve terminals by a unique mode of binding and enter into their cytosol where they cleave SNARE proteins, thus inhibiting the neurotransmitter release. The specificity and rapidity of binding, which limits the anatomical area of its neuroparalytic action, and its reversible action make BoNT a valuable pharmaceutical to treat neurological and non-neurological diseases determined by hyperactivity of cholinergic nerve terminals. This review reports the progress on our understanding of how BoNTs cause nerve paralysis highlighting the different steps of their molecular mechanism of action as key aspects to explain their extreme toxicity but also their unique pharmacological properties.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28(14):3689–3696
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Working Group on Civilian Biodefense et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070
Bernard C (1866) Leçons sur les propriétés des tissus vivants. Paris, reproduced by Lighting Source UK, Milton Keynes, UK
Bhattacharjee Y (2011) Biosecurity. Panel selects most dangerous select agents. Science 332:1491–1492
Brunger AT, Rummel A (2009) Receptor and substrate interactions of clostridial neurotoxins. Toxicon 54(5):550–560
Carli L, Montecucco C, Rossetto O (2009) Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve 40:374–380
Chanaday NL, Cousin MA, Milosevic I, Watanabe S, Morgan JR (2019) The synaptic vesicle cycle revisited: new insights into the modes and mechanisms. J Neurosci 39(42):8209–8216
Chatham-Stephens K, Fleck-Derderian S, Johnson SD, Sobel J, Rao AK, Meaney-Delman D (2018) Clinical features of foodborne and wound Botulism: a systematic review of the literature, 1932–2015. Clin Infect Dis 66(1):S11–S16
Colasante C, Rossetto O, Morbiato L, Pirazzini M, Molgó J, Montecucco C (2013) Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol 48:120–127
Dong M, Masuyer G, Stenmark P (2019) Botulinum and tetanus neurotoxins. Annu Rev Biochem 88:811–837
Doxey AC, Mansfield MJ, Montecucco C (2018) Discovery of novel bacterial toxins by genomics and computational biology. Toxicon 147:2–12
Doxey AC, Mansfield MJ, Lobb B (2019) Exploring the evolution of virulence factors through Bioinformatic data mining. mSystems 4(3):e00162
Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol 15:325–336
Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C (2004) Different types of botulinum toxin in humans. Mov Disord 19(Suppl 8):S53–S59
Erbguth FJ (2004) Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 19(Suppl 8):S2–S6
Fleck-Derderian S, Shankar M, Rao AK, Chatham-Stephens K, Adjei S, Sobel J, Meltzer MI, Meaney-Delman D, Pillai SK (2017) The epidemiology of foodborne Botulism outbreaks: a systematic review. Clin Infect Dis 66(suppl_1):S73–S81
Fogolari F, Tosatto SC, Muraro L, Montecucco C (2009) Electric dipole reorientation in the interaction of botulinum neurotoxins with neuronal membranes. FEBS Lett 583(14):2321–2325
Gart MS, Gutowski KA (2016) Overview of Botulinum toxins for aesthetic uses. Clin Plast Surg 43(3):459–471
Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335(6071):977–981
Harper CB, Papadopulos A, Martin S, Matthews DR, Morgan GP, Nguyen TH, Wang T, Nair D, Choquet D, Meunier FA (2016) Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep 6:19654
Hughes R, Whaler BC (1962) Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by cl. Botulinum type a toxin. J Physiol 160:221–233
Jahn R, Scheller RH (2006) SNAREs--engines for membrane fusion. Nat Rev 7(9):631–643
Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10):898–902
Lam KH, Jin R (2015) Architecture of the botulinum neurotoxin complex: a molecular machine for protection and delivery. Curr Opin Struct Biol 31:89–95
Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201–207
Mazzocchio R, Caleo M (2015) More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist 21:44–61
Miles GB, Hartley R, Todd AJ, Brownstone RM (2007) Spinal cholinergic interneurons regulate the excitability of motoneurons during locomotion. Proc Natl Acad Sci U S A 104(7):2448–2453
Montal M (2010) Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79:591–617
Montecucco C (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11:314–317
Montecucco C, Rasotto MB (2015) On botulinum neurotoxin variability. MBio 6:e02131–e02114
Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C (2009) The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun 380(1):76–80
Nuemket N, Tanaka Y, Tsukamoto K, Tsuji T, Nakamura K, Kozaki S, Yao M, Tanaka I (2011) Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism. Biochem Biophys Res Commun 411:433–439
Pantano S, Montecucco C (2014) The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci 71:793–811
Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, Cuervo P, Cheng LW, Derman Y, Dorner BG, Fisher A, Hill KK, Kalb SR, Korkeala H, Lindstrom M, Lista F, Luquez C, Mazuet C, Pirazzini M, Popoff MR, Rossetto O, Rummel A, Sesardic D, Singh BR, Stringer SC (2017) Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins 9(1):38
Pellet S, Tepp WH, Johnson EA (2019) Critical analysis of neuronal cell and the mouse bioassay for detection of botulinum neurotoxins. Toxins 11(12):E713. https://doi.org/10.3390/toxins11120713
Pirazzini M, Azarnia Tehran D, Zanetti G, Megighian A, Scorzeto M, Fillo S, Shone CC, Binz T, Rossetto O, Lista F et al (2014) Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8:1870–1878
Pirazzini M, Azarnia Tehran D, Leka O, Zanetti G, Rossetto O, Montecucco C (2016) On the translocation of Botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta 1858:467–474
Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200–235
RamÃrez-JarquÃn UN, Tapia R (2018) Excitatory and inhibitory neuronal circuits in the spinal cord and their role in the control of motor neuron function and degeneration. ACS Chem Neurosci 9(2):211–216
Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M (2011) Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 31(44):15650–15659
Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O, Caleo M, Schiavo G (2012) Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8(12):e1003087
Rossetto O, Montecucco C (2019) Tables of toxicity of Botulinum and tetanus neurotoxins. Toxins (Basel) 11(12):E686
Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, Lozzi L, Shone CC (1994) SNARE motif and neurotoxins. Nature 372(6505):415–416
Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12(8):535–549
Rossetto O, Pirazzini M, Lista F, Montecucco C (2019) The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol 21(11):e13037
Rummel A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 364:61–90
Simpson L (2013) The life history of a botulinum toxin molecule. Toxicon 68:40–59
Sobel J (2005) Botulism. Clin Infect Dis 41(8):1167–1173
Stern D, Weisemann J, Le Blanc A, von Berg L, Mahrhold S, Piesker J, Laue M, Luppa PB, Dorner MB, Dorner BG, Rummel A (2018) A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency. PLoS Pathog 14(5):e1007048
Sudhof TC, Rothman JE (2009) Membrane fusion: grappling with SNARE and SM proteins. Science 323(5913):474–477
Sugawara Y, Matsumura T, Takegahara Y, Jin Y, Tsukasaki Y, Takeichi M, Fujinaga Y (2010) Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol 189:691–700
Sutton RB, Fasshauer D, Jahn R, Brunger AT (1998) Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395(6700):347–353
Swaminathan S (2011) Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 278(23):4467–4485
Zagoraiou L, Akay T, Martin JF, Brownstone RM, Jessell TM, Miles GB (2009) A cluster of cholinergic premotor interneurons modulates mouse locomotor activity. Neuron 64(5):645–662
Zanetti G, Azarnia Tehran D, Pirazzini M, Binz T, Shone CC, Fillo S, Lista F, Rossetto O, Montecucco C (2015) Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol 98(3):522–530
Zhang Y, Varnum SM (2012) The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides. Biochimie 94:920–923
Zhang S, Berntsson RP, Tepp WH, Tao L, Johnson EA, Stenmark P, Dong M (2017) Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC. Nat Commun 8(1):1637
Acknowledgements
Work in the author’s laboratory is supported by University of Padova, CNR and the Ministry of Defence research project RI.PA.NE.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rossetto, O., Pirazzini, M., Fabris, F., Montecucco, C. (2020). Botulinum Neurotoxins: Mechanism of Action. In: Whitcup, S.M., Hallett, M. (eds) Botulinum Toxin Therapy. Handbook of Experimental Pharmacology, vol 263. Springer, Cham. https://doi.org/10.1007/164_2020_355
Download citation
DOI: https://doi.org/10.1007/164_2020_355
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-66305-6
Online ISBN: 978-3-030-66306-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)